PUBLISHER: Allied Market Research | PRODUCT CODE: 1139891
PUBLISHER: Allied Market Research | PRODUCT CODE: 1139891
The global post-traumatic stress disorder treatment market was valued at $15,976.64 million in 2021 and is projected to reach $26,060.75 million by 2031, registering a CAGR of 4.9% from 2022 to 2031. Post-traumatic stress disorder is a serious condition related to mental health. It is caused due to life-threatening events, recurrent anxiety, sex abuse & internal reminder of traumatic events. The symptoms of the disorder include flashbacks, nightmares, swings of mood, changes in physical activities & uncontrollable thoughts about the incident that may cause a stressed condition for the patient. Post-Traumatic Stress Disorder (PTSD) is a mental disorder characterized by disturbing symptoms that interfere with daily functioning. PTSD symptoms may start very quickly following a traumatic event, or they might not appear for years after the event including intrusive memories or reliving of the experience, avoidance of anything that reminds the person of the trauma, negative changes in thinking or mood that are a result of the trauma and which interfere with daily functioning, and changes in the person's emotional reactions to everyday events.
The global post-traumatic stress disorder treatment market is majorly driven by an increase in the prevalence of post-traumatic stress disorder due to the increase in the number of accidents or incidents across the globe. In addition, an increase in clinical trials and a rise in the geriatric population drives the growth of the market in upcoming years. However, side effects associated with drug treatment are expected to hamper the market. Moreover, the increase in research & development activities for antidepressant drugs against post-traumatic stress disorder, rise in government initiatives for post-traumatic stress disorder treatment management, and increase in healthcare expenditure in developing countries are the key factor that boosts the growth of the market.
The post-traumatic stress disorder treatment market is segmented on the basis of treatment type, age group, end-user, and region. On the basis of treatment type, the market is divided into drugs and psychotherapy. By drugs, the market is classified into antidepressants, antipsychotics, beta-blockers, benzodiazepines, and others. Psychotherapy, the market is divided into cognitive behavior therapy, psychodynamic therapy, and others. On the basis of age, the market is divided into geriatric, pediatric, and adults. By end-user, the market is classified into hospitals, outpatients' clinics, mental health centers, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
.The key players operating in the global post-traumatic stress disorder treatment market are Acadia Healthcare, Behavioral Health Network, Inc., CareTech Holdings Plc, GlaxoSmithKline Plc, Pfizer, Inc, Viatris, Inc, Strategic Behavioral Health, Ascension Seton, North Range Behavioral Health, Pyramid Healthcare and Eily Lilly and Company.
Key Benefits For Stakeholders
Key Market Segments
By Treatment Type
By Age Group
By End User
By Region